Hatteras Venture Partners
ActiveDurham, NCBiotechnology, Healthcare, PharmaceuticalsLast fund filed December 2021
7 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| Hatteras Venture Partners VII | December 2021 | $250M | $135M | 88 |
| Hatteras Venture Partners VI | April 2019 | $250M | $137M | 64 |
| Hatteras Venture Partners V | August 2015 | $150M | $91M | 34 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
7 partners are named across this firm’s filings, 7 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Douglas Reed | Selective | Medical devices | 14 | 2 |
Classified sectors of Hatteras Venture Partners’s own portfolio companies, based on 8 with a verified or cited source.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Hatteras Venture Partners’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Firm | Shared boards | Companies |
|---|---|---|
| Atlas Venture | 2 | Lysosomal Therapeutics, Vigil Neuroscience |
| Capra CLO Founders | 1 | Atsena Therapeutics |
| Clarus | 1 | GRAYBUG VISION |
| Noro-Moseley Partners | 1 |
| John Crumpler | Selective | Healthcare services | 11 | 2 |
| Michael Dial | Selective | Biotech & pharma | 7 | 2 |
| Christy Shaffer | Slowing | Biotech & pharma | 10 | 1 |
| Clay Thorp | Slowing | Biotech & pharma | 10 | 1 |
| Jeffrey Terrell | Quiet | None listed | 3 | 0 |
| Robert Ingram | Quiet | None listed | 3 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
| Elligo Health Research |
| Sofinnova Venture Partners | 1 | Atsena Therapeutics |
| SV Life Sciences | 1 | Ribometrix |
| Versant Venture Capital | 1 | iVEAcare |
| Vida Ventures | 1 | Vigil Neuroscience |
| Virtuoso-mccarran | 1 | Ribometrix |
| Vivo Innovation | 1 | Perfuse Therapeutics |
A shared board seat: a company where filings name a Hatteras Venture Partners partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.